Potential biomarkers for early detection of pancreatic ductal adenocarcinoma

8Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

Pancreatic cancer has the highest mortality amongst all major organ cancers. Early detection is key to reduce deaths related to pancreatic cancer. However, early detection has been challenged by the lack of non-invasive biomarkers with enough sensitivity and specificity to allow for screening. The gold standard is still carbohydrate antigen (CA 19-9), against which all new biomarkers must be evaluated. In this paper, we describe recent progress in the development of new pancreatic cancer biomarkers, focusing on proteins, metabolites, and genetic and epigenetic biomarkers. Although several promising biomarkers have been identified, they are all derived from retrospective studies and additional prospective studies are needed to confirm their clinical validity.

Cite

CITATION STYLE

APA

Kriz, D., Ansari, D., & Andersson, R. (2020, December 1). Potential biomarkers for early detection of pancreatic ductal adenocarcinoma. Clinical and Translational Oncology. Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s12094-020-02372-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free